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The Overlap of Lung Tissue 
Transcriptome of Smoke Exposed 
Mice with Human Smoking and 
COPD
Ma’en Obeidat  1, Anna Dvorkin-Gheva2, Xuan Li1, Yohan Bossé  3,4, Corry-Anke Brandsma5, 
David C. Nickle6, Philip M. Hansbro7,8, Rosa Faner9, Alvar Agusti9,10, Peter D. Paré1,11, 
Martin R. Stampfli2,12 & Don D. Sin1,11
Genome-wide mRNA profiling in lung tissue from human and animal models can provide novel insights 
into the pathogenesis of chronic obstructive pulmonary disease (COPD). While 6 months of smoke 
exposure are widely used, shorter durations were also reported. The overlap of short term and long-
term smoke exposure in mice is currently not well understood, and their representation of the human 
condition is uncertain. Lung tissue gene expression profiles of six murine smoking experiments (n = 48) 
were obtained from the Gene Expression Omnibus (GEO) and analyzed to identify the murine smoking 
signature. The “human smoking” gene signature containing 386 genes was previously published in 
the lung eQTL study (n = 1,111). A signature of mild COPD containing 7 genes was also identified 
in the same study. The lung tissue gene signature of “severe COPD” (n = 70) contained 4,071 genes 
and was previously published. We detected 3,723 differentially expressed genes in the 6 month-
exposure mice datasets (FDR <0.1). Of those, 184 genes (representing 48% of human smoking) and 
1,003 (representing 27% of human COPD) were shared with the human smoking-related genes and 
the COPD severity-related genes, respectively. There was 4-fold over-representation of human and 
murine smoking-related genes (P = 6.7 × 10−26) and a 1.4 fold in the severe COPD -related genes 
(P = 2.3 × 10−12). There was no significant enrichment of the mice and human smoking-related genes 
in mild COPD signature. These data suggest that murine smoke models are strongly representative of 
molecular processes of human smoking but less of COPD.
Chronic obstructive pulmonary disease (COPD) affects 300 million people and is currently the third lead-
ing cause of death worldwide1. Although the exact mechanisms of pathophysiology are unknown, it is widely 
accepted that COPD is under genetic and environmental control with cigarette smoking being the most impor-
tant modifiable risk factor in the Western world2.
Recent advances in genomics have enabled genome-wide mRNA profiling to gain novel insights into COPD 
pathogenesis3–8. While these studies report genes associated with disease phenotypes or smoking, follow up 
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in vitro and in vivo studies are required to disentangle mechanism and establish causality. Of the in vivo models, 
mice are commonly used to determine the effects of cigarette smoking in the pathogenesis of COPD (reviewed in 
references9–15). Generally, 6 months of smoke exposure is used to induce histological and functional abnormal-
ities in murine lungs that mimic those of human disease including emphysema, airway remodeling and pulmo-
nary hypertension, though the changes are relatively mild compared with those observed in long-term human 
smokers16. However, more recent methods can replicate these features as well as the impairment of lung function 
in 8 weeks with nose-only exposure17,18. Shorter exposure times are generally used to model inflammatory mech-
anisms11,19. How gene expression profiles compare between short term and long term smoke exposure is currently 
not well understood. Moreover, although mice are commonly employed to model COPD, the extent to which 
murine experiments mimic the human condition is uncertain.
The availability of genome-wide transcriptomic signatures in lung tissue enables comparisons between human 
and murine models following short- and long-term cigarette smoke exposures. The aims of this study were to 
compare and contrast the molecular changes in murine models following short and long term exposures with the 
molecular changes in human lungs induced by cigarette smoke. Most importantly, we sought to determine, if the 
human “COPD” lung tissue gene expression signature is captured in murine lungs exposed to cigarette smoke.
Results
Murine gene expression signatures following short-term smoke exposure. The six murine studies 
involving short term smoke exposure are summarized in Table 1.
Principal component analysis (PCA) performed on the 10,634 common genes led to the exclusion of one sam-
ple of air exposed mice from study GSE55127, which was a clear outlier. The resulting PCA plot shows that the 6 
studies were homogenous in terms of expression changes and demonstrated clustering based on smoke-exposure 
status (Fig. 1).
Gene expression analysis of the pooled dataset from the 6 murine studies identified 3,723 genes that were 
differentially expressed at an FDR cutoff of 10%. Of the differentially expressed genes, 3,519 genes had 3,687 
human gene orthologs. The use of a more stringent FDR cutoff of 5% or 1% reduced the number of differentially 
expressed genes to 3,051 and 2,021, respectively. The most significant differentially expressed genes were cxcl1 
(C-X-C motif chemokine ligand 1), gpnmb (glycoprotein nmb) and cd84 (Table 2).
Murine gene expression signatures following long-term smoke exposure. The gene expression 
analysis in the pooled dataset from the two murine studies which involved 6 months smoke exposure identified 
3,106 genes that were differentially expressed at an FDR cutoff of 10%. Of these, 2,989 genes had 3,116 human 












GSE33561 6–7 AKR/J M 6–8 2/3 90 2R4F
GSE33512 16 C57BL/6 M 12 4/4 100–120 1R3F
GSE52509 16 C57BL/6 F 8–10 3/3 500 3R4F
GSE17737 12 C57BL/6 F 12 5 FA/5 NA NA
GSE55127 8 BALB/C F 6–8 4/5 >600 3R4F*
GSE18344 8 CD-1 F 13 4/4 750 2R4F
GSE52509 24 C57BL/6 F 24 3/3 500 3R4F
GSE17737 24 C57BL/6 F 24 6 FA/6 NA NA
Table 1. The 6 murine studies used to detect smoking gene signature. RA: room air; FA: forced air; CS: cigarette 
smoke; *filters removed.
Figure 1. Principal component analysis of the 6 short-term exposure murine studies used to detect smoking 
gene signature.
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Comparison of human versus murine lung gene expression profiles related to cigarette smoke 
exposure or smoking status. We next sought to evaluate the extent of overlap between murine and 
human smoking signatures. A total of 184 genes, representing 48% of human smoking signature genes, were 
shared between the human and short-term mice smoking exposure. Of those, 148 and 14 genes were up- and 
down-regulated in both datasets, respectively and 22 had an opposite direction of effect between the two data-
sets. A circos plot comparing the human lung tissue smoking signature of 386 genes (current vs. never smokers) 
with the 3,687 genes related to short term exposure in mice is shown in Fig. 2. When compared to the long-term 
exposure murine models (6 months), 168 genes demonstrated overlap with the human signature and of these, 
146 and 9 genes were up- and down-regulated in both datasets, respectively and 13 had an opposite direction of 
effect. Comparing the human smoking signature to both short and long-term smoking exposure in mice, 139 
genes overlapped in all three studies, and of these 121 and 8 genes were up and down-regulated in all three studies 
and 10 genes had an opposite direction of effect in the human dataset. A list of the top 20 (based on the P values in 
the human data) overlapping genes is shown in Table 3. The list of overlapping genes included aryl-hydrocarbon 
receptor repressor (AHRR), CYP1B1 cytochrome P450 family 1 subfamily B member 1 (CYP1B1), C-X-C motif 
chemokine ligand 16 (CXCL16), NAD(P)H quinone dehydrogenase 1 (NQO1) and serpin family D member 1 
(SERPIND1).
The 139 overlapping genes were enriched in numerous gene ontology processes related to defense and 
immune response, glycosphingolipid and ceramide catabolic processes (Table 4).
Comparison of murine and human smoking signature with COPD lung-tissue signature. To 
gain insights into the translational potential of the smoking gene signature, we tested for overlap with published 
human COPD signatures in lung tissue. The Faner et al. dataset included 70 former smokers with COPD from 
GOLD grades 1 to 44. Using this dataset we identified 4,071 genes that were differentially expressed between 
patients in GOLD 3/4 vs. GOLD 1/2. A total of 1,003 “smoking” genes (27%) from the short-term murine smok-
ing experiments overlapped with the “severe COPD signature” from the Faner et al. Comparison of the human 
smoking and COPD signature showed that 116 “smoking” genes (30%) from the lung eQTL dataset overlapped 
with the “severe COPD signature” of Faner et al. (Fig. 3). Of the 3,116 “smoking” genes derived from the 6 month 
exposure model in mice, 1,958 (53%) overlapped with the “smoking” genes derived from the short-term smoke 
exposure in mice and 168 genes (44%) overlapped with the human smoking signature from the eQTL study, and 
914 genes (22%) overlapped with the “severe COPD” signature in the Faner et al. study.
Overall, 48 genes were common to both smoking signatures in mice (short and long term exposure) as well as 
the human smoking and severe COPD signatures (Supplementary Table 1). All of these genes except one showed 
the same direction of effect across studies i.e. up-regulated in smoking and in COPD or vice versa. These 48 genes 
were enriched in a number of gene ontology processes that are summarized in Table 4 including antigen process-
ing and presentation, pyridine and nicotinamide nucleotide metabolic process, catabolic processes, transmem-
brane transport, oxidoreduction coenzyme metabolic process, and carbohydrate and glucose catabolic processes.
An additional relevant question to this work was whether or not smoking signature of mice and human will 
show enrichment in mild COPD as opposed to severe COPD signature. To answer this question, we analyzed 
the transcriptome of lung tissue eQTL study comparing mild COPD cases to controls. At and FDR <0.1 cutoff, 
Short term (8–16 week) smoke exposure 24 week smoke exposure
Gene logFC P.Value FDR Gene logFC P.Value FDR
Cxcl1 2.24 1.41E-16 1.50E-12 Zranb3 2.52 8.71E-19 9.21E-15
Gpnmb 2.04 5.80E-15 3.08E-11 Pld3 1.23 8.27E-17 4.37E-13
Cd84 0.96 1.51E-14 5.35E-11 Noxo1 1.84 6.08E-16 2.14E-12
Cd68 1.61 2.18E-14 5.80E-11 Ctsk 2.69 9.76E-16 2.58E-12
Slc7a11 1.90 3.45E-14 7.34E-11 Lhfpl2 1.68 1.30E-15 2.76E-12
Gdf15 1.25 4.44E-14 7.87E-11 Saa3 4.13 2.80E-15 4.93E-12
Tnfaip2 0.66 6.33E-14 9.61E-11 Lgals3 1.00 4.43E-15 5.04E-12
Ccl3 2.23 1.07E-13 1.42E-10 Mmp12 3.77 4.56E-15 5.04E-12
Asgr1 −1.02 1.84E-13 2.11E-10 Clec4n 1.77 4.61E-15 5.04E-12
Zranb3 1.84 1.98E-13 2.11E-10 Lrp12 1.35 4.77E-15 5.04E-12
Ctsk 2.00 2.25E-13 2.17E-10 Itih4 1.64 1.03E-14 9.87E-12
Lgals3 1.11 2.53E-13 2.17E-10 Cstb 0.69 1.41E-14 1.25E-11
Saa3 3.74 2.66E-13 2.17E-10 Ccl9 1.55 1.53E-14 1.25E-11
Myo5a 1.01 4.07E-13 2.94E-10 Ctsz 1.09 2.76E-14 2.08E-11
Cxcl5 2.92 4.15E-13 2.94E-10 Zmynd15 1.40 3.48E-14 2.45E-11
Cstb 0.70 5.30E-13 3.52E-10 Cd68 1.75 4.27E-14 2.78E-11
Lhfpl2 1.20 7.04E-13 4.04E-10 Npy 2.13 4.47E-14 2.78E-11
Cyp1b1 2.43 7.16E-13 4.04E-10 Lgmn 0.79 5.20E-14 3.06E-11
Hmox1 0.80 7.22E-13 4.04E-10 Gpnmb 2.39 1.21E-13 6.72E-11
Mmp12 3.29 1.14E-12 6.04E-10 Marco 2.29 1.66E-13 8.79E-11
Table 2. The top 20 smoking related genes in the murine lungs. LogFC: log fold change. FDR: false discovery rate.
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this analysis identified 7 genes differentially expressed between mild COPD cases and controls (Supplementary 
Table 2).
To quantify the extent of overlap among the different studies, we used a Fisher’s exact test to determine 
whether there was significant enrichment of the human smoking or disease signatures in murine smoking sig-
natures (Table 5). Differentially expressed genes from all the studies showed an over-representation in the mice 
data. The strongest enrichment was observed between the short and long-term mice smoking signatures (5.5 
fold enrichment, p = 1.6 × 10−309). The results also showed almost 4-fold enrichment of human smoking genes 
in the mice smoking signature (P = 6.7 × 10−26). Of the lung tissue disease signatures, the severe COPD signature 
from the study of Faner et al. was over-represented in the short term murine smoking signature (1.2 fold enrich-
ment, P = 4.2 × 10−05) and was also over-represented in the 6 month smoking models (1.4 fold, p = 2.3 × 10−12). 
Interestingly though, the mild COPD signature was not over-represented in the mice or human smoking 
signatures.
Integrative genomics of smoking related genes common to both human and murine lungs. To 
extend the gene expression findings to large scale human genetic studies of lung function we investigated whether 
any of the genes whose expression was related to smoking in both human and murine lungs were under genetic 
control in human lung tissue (i.e. were lung expression quantitative trait loci [eQTLs]). We found that 60 of the 
139 genes have significant eQTLs (10% FDR) with a total of 7834 eQTLs.
Next, we restricted the analysis to the most significant eQTL per probeset (based on the eQTL p values) which 
led to a final SNP list of 73 (some SNPs were top eQTLs for more than one probeset). The 73 eQTLs were tested 
for associations with lung function in publically available large-scale genome-wide association studies (GWASs) 
datasets: SpiroMeta20 and the UKBilEVE studies21. The results for SNPs with p < 0.05 are shown in Supplementary 
Table 3 for eQTLs that had p value < 0.05 for association with lung function in SpiroMeta or UKBiLEVE. The only 
SNP that was associated with lung function at FDR < 0.05 was rs1081512, which was an eQTL for CTSS (cathep-
sin S) gene. It was also strongly associated with FEV1 in the SpiroMeta GWAS (P = 6.07E-05, FDR = 0.004).
Figure 2. Circos plot of smoking related genes overlapping between human and murine lungs. Genes are 
shown based on their chromosomal positions (in the human genome) in the outer most circle. The first circle 
from the inside represents genes from the short-term smoke exposed mouse while the second circle represents 
genes from the long (24 weeks) term smoke-exposed mouse and the outer most circle represent the human 
smoking-related genes. Each line represents a gene: inward lines labeled in orange represent down-regulated 
genes while outward lines in red represent up-regulated genes. Gene symbols are colored accordingly with down 
and up-regulated genes depicted as orange and red, respectively. The length of the line is proportional to the –
log10 p values for differential expression in human and for the –log10 FDR values in murine data. Gene symbols 
in black are genes that showed opposite direction of effect between mice and humans.
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Discussion
Pre-clinical animal models represent a valuable tool for understanding the pathogenesis of COPD and identi-
fying novel therapeutics and biomarkers. However, to date, there has been a scarcity of data that have directly 
compared molecular profiles in the lungs of smoke-exposed mice that have been used to model COPD against 
those of human lungs in order to determine how (and if) ‘disease’ in these animals is representative of the human 
condition. A recent study by Yun et al. reported the overlap of mice and human smoking signatures and identi-
fied many overlapping genes, but very few that were shared with COPD signature22. Earlier, Morissette et al. also 
investigated the overlap of genes differentially affected by smoking in both mice and human lung tissues8. They 
found an enrichment of genes that were significantly modulated by cigarette smoke in humans and in mice, and 
that the majority of biological functions modulated by cigarette smoke in humans were also affected in mice8. 
Both studies, however, did not compare short vs. long term smoke exposures of mice and did not identify genetic 
variants relating to the expression of genes of interest.
By directly comparing and contrasting the gene expression profiles of smoke-exposed (both long and 
short-term) murine lungs against a large number of human lungs of current and ex smokers across the full spec-
trum of COPD severity (and also versus former smokers), we have made several important observations. They 
include: (1) the identification of overlapping 3,723 and 3,106 genes that were differentially expressed in short 
and long-term smoke exposure in murine lungs, respectively (5.5-fold enrichment of short term signature in 
the long-term signature, P = 1.6 × 10−309), suggesting that acute transcriptomic changes in the lungs related to 
cigarette smoking are largely retained over longer term, when morphologic appearances of emphysema, airway 
remodeling and mild pulmonary hypertension become measurable in mice; (2) a significant overlap of genes in 
smoke-exposed murine lungs (48% from short-term exposure and 44% from long-term exposures) with those 
of human lungs explanted from current smokers. There was a 3.8 fold enrichment of the human “smoking” lung 
signature in the murine lungs (p = 1.6–6.7 × 10−26); and (3) a 1.4 fold enrichment of severe COPD gene expres-
sion signature in the human “smoking” lung signature (p = 3.5 × 10−3), with a 1.2 fold enrichment in short-term 
smoke- exposed murine (p = 4.2 × 10−5) and a 1.4 fold enrichment in long-term smoke-exposed murine lungs 
(p = 2.3 × 10−12). There were 48 genes that were common to the lungs of both smoked-exposed mice and current 
smokers and severe COPD, suggesting that the long term smoking exposure of mice results in transcriptomic 
changes that are also found in severe COPD patients even following smoking cessation. Of these the association 
of the gene encoding for cathepsin S was also supported in large scale human genetics studies of lung function. 
Finally, the murine and human smoking signatures were not over-represented in mild COPD signature, suggest-
ing that overall mice models are better representative of smoking but less so of COPD in humans.
The smoking genes that overlapped between murine and human lung tissue included aryl hydrocarbon recep-
tor repressor (AHRR), cytochrome P450 family 1 subfamily B member 1 (CYP1B1), C-X-C motif chemokine 
ligand 16 (CXCL16), NAD(P)H quinone dehydrogenase 1 (NQO1) and serpin family D member 1 (SERPIND1), 
all of which were up-regulated in the lung tissues of smokers. The AHRR gene has been well studied and a large 
number of publications have reported changes in its methylation and expression related to smoking23,24. AHRR 
encodes a ligand-activated transcription factor that inhibits the aryl hydrocarbon receptor pathway, which, in 
turn, increases the expression of xenobiotic-metabolizing enzymes that break down environmental pollutants, 


















AHRR 1.81 4.67E-10 5.71E-08 1.27 1.54E-07 6.43E-06 2.61 3.28E-20
CYP1B1 2.43 7.16E-13 4.04E-10 0.89 9.33E-11 1.28E-08 2.00 6.12E-20
CXCL16 0.32 4.03E-05 4.55E-04 0.65 7.55E-10 7.83E-08 0.75 8.74E-18
NQO1 1.60 9.10E-09 6.13E-07 0.30 3.52E-06 7.90E-05 0.93 1.17E-17
SERPIND1 0.50 1.86E-07 6.37E-06 0.76 1.08E-08 7.24E-07 3.73 5.20E-17
PGD 0.56 1.38E-11 3.54E-09 0.25 8.56E-05 1.04E-03 0.72 6.37E-17
NEK6 0.57 9.69E-10 9.81E-08 0.71 5.95E-08 2.94E-06 1.02 8.47E-17
SLC31A1 0.15 8.04E-04 5.11E-03 0.13 3.00E-03 1.77E-02 1.02 1.15E-16
ALOX5AP 0.52 1.42E-07 5.08E-06 0.49 2.06E-07 8.11E-06 0.65 3.07E-16
TREM2 1.26 9.92E-11 1.66E-08 1.50 8.80E-08 4.05E-06 1.74 4.39E-16
COL8A2 −0.30 6.87E-06 1.12E-04 −0.23 1.71E-03 1.14E-02 1.00 5.82E-16
OLR1 0.97 4.97E-08 2.19E-06 0.89 1.62E-06 4.17E-05 0.60 6.27E-16
ZNF365 −0.22 9.04E-03 3.48E-02 −0.28 1.52E-05 2.64E-04 1.63 6.52E-16
ATP6V0D2 1.24 3.48E-10 4.56E-08 1.04 1.11E-06 3.18E-05 2.56 7.64E-16
NCF2 0.55 4.87E-07 1.37E-05 0.52 4.29E-07 1.47E-05 0.74 1.13E-15
ACP5 0.88 1.43E-08 8.33E-07 1.11 1.14E-05 2.10E-04 1.12 1.46E-15
CYBB 0.60 1.40E-05 1.96E-04 0.61 5.37E-05 7.16E-04 1.22 2.08E-15
DNASE2B −0.29 7.95E-04 5.06E-03 −0.37 3.95E-04 3.56E-03 2.11 2.56E-15
GM2A 0.10 2.34E-02 7.40E-02 0.16 8.51E-04 6.60E-03 0.78 5.31E-15
GNGT2 0.44 1.53E-04 1.34E-03 0.19 2.19E-02 7.97E-02 0.87 5.31E-15
Table 3. Top 20 smoking-related genes overlapping between human and murine lungs.
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involved in the conversion of procarcinogens in cigarette smoke to carcinogenic intermediates26. The expression 
of CYP1B1 was found to be up-regulated in a number of tissues including the lungs following cigarette smoke 
exposure27. NQO1 is an enzyme involved in the detoxification of mutagenic and carcinogenic quinones, by pre-
venting electron transfer and the generation of free radicals and reactive oxygen species28 and converting the 
intermediates to the less toxic hydroquinones29. SERPIND1 encodes the heparin cofactor II (HCII), which is an 
endogenous thrombin inhibitor that protects against vascular remodeling and atherosclerosis via its inhibition 
of thrombin in the vascular wall30. It may also play a role in enhancing cell motility and promoting metastasis in 
non-small cell lung cancer31.
Almost half (48%) of genes making up the human smoking signature overlapped with those differentially 
expressed in the murine smoked lung. The overlapping genes were enriched in processes related to host defense 
and immune responses including those that involve glycosphingolipid and ceramide catabolic pathways. These 
processes are well known to be affected by smoking32–34. The significant enrichment of human smoking signa-
tures in the murine lung following short and long-term smoke exposure suggests that mice models of smoking 
do, in fact, reflect molecular changes that occur with smoking in humans. There are some caveats, however. For 
instance, we found that for ~6% of the human “smoking” lung genes the change in gene expression in the murine 
lungs was in the opposite direction. This may be due to different molecular responses to smoking between human 
and mice lungs. Alternatively, it may reflect the duration of cigarette smoke exposure between humans and mice. 
The duration of smoke exposure for mice ranged from 6–24 weeks compared to years of smoking in humans. 
However, this can be considered representative in a mouse that have an average life span of 1.5–2 years.
Using integrative genomics we showed that 43% of the overlapping smoking signature genes were under 
genetic control in lung tissue. The SNP that showed the strongest association with lung function in large scale 
genetic studies was an eQTL for the cathepsin S gene (CTSS). The CTSS gene encodes an elastin-degrading 
proteinase which is highly expressed by macrophages and dendritic cells35 and plays an active role in adaptive 
immune responses36. The major inhibitor of cathepsin S is cystatin C which was recently identified as a COPD 
causal gene using an integrative genomics approach37.
Our current study has some limitations. First, the sample sizes for the studies included may have led to false 
negative results. Second, the unit of analysis in this study was gene expression, yet translation and post trans-
lational modifications of proteins in lung tissue may also be similar or different between mice and human and 
between smokers with and without COPD. Third, mice have different pathophysiology compared to humans. For 
example, studies have shown that in humans, the loss of small airways proceeds the development of emphysema 
Gene ontology (GO) pathway P value FDR
The 139 genes overlapping the mice and human smoking signatures
Immune response 2.20E-11 9.89E-09
Defense response 1.15E-11 9.89E-09
Glycosphingolipid catabolic process 1.78E-10 5.33E-08
Glycolipid catabolic process 3.53E-10 7.93E-08
Immune system process 8.30E-10 1.49E-07
Inflammatory response 1.23E-09 1.58E-07
Phagosome maturation 1.08E-09 1.58E-07
Ceramide catabolic process 6.79E-09 7.63E-07
Response to stimulus 8.71E-09 8.70E-07
Sphingolipid catabolic process 1.94E-08 1.74E-06
Response to chemical stimulus 2.17E-08 1.77E-06
Membrane lipid catabolic process 2.65E-08 1.99E-06
Glycosphingolipid metabolic process 5.50E-08 3.80E-06
Lipid storage 2.43E-07 1.56E-05
Antigen processing and presentation of peptide antigen 6.98E-07 4.18E-05
The 48 genes overlapping smoking in mice and human and COPD signatures
Antigen processing and presentation of peptide antigen via MHC class I 2.00E-04 2.85E-02
Pyridine nucleotide metabolic process 4.00E-04 2.85E-02
Catabolic process 4.00E-04 2.85E-02
Nicotinamide nucleotide metabolic process 4.00E-04 2.85E-02
Organic substance catabolic process 6.00E-04 2.85E-02
Pyridine-containing compound metabolic process 6.00E-04 2.85E-02
Transmembrane transport 7.00E-04 2.85E-02
Oxidoreduction coenzyme metabolic process 7.00E-04 2.85E-02
Carbohydrate catabolic process 8.00E-04 2.90E-02
Carbohydrate derivative catabolic process 9.00E-04 2.93E-02
Glucose catabolic process 1.50E-03 4.35E-02
Antigen processing and presentation of exogenous peptideantigen via MHC class I 1.60E-03 4.35E-02
Table 4. Gene ontology processes enriched in human and murine smoking overlapping genes.
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before COPD is detectable with spirometry38. Finally, the cellular heterogeneity of murine and human lung tissue 
samples may have limited our ability to detect overlapping signatures.
In conclusion, the current study uncovered a strong similarity between short and long term smoking effects 
on lung transcriptome in mice and a strong overlap with the human smoking signature. The study additionally 
uncovered genes common to smoking and COPD signatures in mice and humans which warrants further study.
Methods
Data sources. Human Lung tissue eQTL and smoking signature study. To compare murine lung smoke 
exposure induced gene expression against human smoking gene expression signatures, we used a large human 
dataset that has been previously described. The lung expression quantitative trait loci study (eQTLs) profiled 
1,111 human lung tissue from current and ex-smokers and non-smokers39–42. Briefly, non-tumour lung specimens 
were collected from patients undergoing lung surgery at three different sites: Institut Universitaire de Cardiologie 
et de Pneumologie de Québec (IUCPQ), Laval University (Quebec, Canada), University of British Columbia 
(UBC, Vancouver, Canada) and University of Groningen (Groningen, the Netherlands. Gene expression profil-
ing was performed using an Affymetrix custom array (GPL10379), which contained 51,627 non-control probe-
sets and data were normalized using RMA43. Genotyping was performed using the Illumina Human1M-Duo 
BeadChip array. Genotype imputation was undertaken using the 1000 G reference panel. Following standard 
microarray and genotyping quality controls, data from 1,111 patients were available including 409 from Laval, 
339 from UBC and 363 from Groningen. Association testing for each variant with mRNA expression in either cis 
(within 1 Mb of transcript start site) or in trans (all other combinations) was undertaken separately for each study 
sample, after which the results were meta-analyzed using inverse variance weighting. A genome-wide 10% false 
discovery rate (FDR) was applied to this analysis. The smoking gene signature in the eQTL study has been previ-
ously published7 and consisted of 386 genes that were differentially expressed between current vs. never smokers 
(henceforth referred to as “human smoking signature”).





signature (Bossé et al.)
Severe COPD Signature 
(Faner et al.)







(p = 6.7 × 10−26)
1.2
(p = 4.2 × 10−5)
5.5
(p = 1.6 × 10−309)
3.5
(p = 0.3)
Human Smoking signature 
(Bossé et al.)
3.8
(p = 6.7 × 10−26) NA
1.4
(p = 3.5 × 10−3)
3.8
(p = 1.6 × 10−26)
0*
(p = 1)
Severe COPD Signature 
(Faner et al.)
1.2
(p = 4.2 × 10−5)
1.4
(p = 3.5 × 10−3) NA
1.4
(p = 2.3 × 10−12)
1.6
(p = 0.63)
6 months mouse smoking 
signature
5.5
(p = 1.6 × 10−309)
3.8
(p = 1.6 × 10−26)
1.4
(p = 2.3 × 10−12) NA
4.6
(p = 0.22)






(p = 0.22) NA
Table 5. Enrichment of human smoking and disease signatures in the mice smoking signature. Each cell shows 
the enrichment fold and the P value associated with it for these two studies. *Indicates that there were no 
overlapping genes between mild COPD and human smoking.
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The lung eQTL study was also used to identify mild COPD signature. We performed differential expression 
analysis between mild COPD (FEV1 ≥80% predicted and FEV1/FVC <0.7) and controls (FEV1 ≥80% predicted 
and FEV1/FVC >0.7). The analysis was adjusted for age, sex and smoking status and the sample sizes were 58 
mild COPD patients (12 from Laval and 46 from UBC) and 107 control subjects (11 from Laval and 96 from 
UBC). Results were combined using meta analysis using inverse variance weighting fixed effect model.
All methods were carried out in accordance with relevant guidelines and regulations. Study participants 
informed consent was obtained from all subjects, and data access and analyses protocols were approved by the 
University of British Columbia Office of Research Ethics.
Mouse gene expression data. Lung gene expression profiles of six publically available datasets (n = 48 samples) 
were obtained from the Gene Expression Omnibus (GEO) (accession numbers GSE33561, GSE33512, 
GSE52509, GSE17737, GSE55127, GSE18344)44. GSE33512, GSE55127, GSE52509 and GSE33561 datasets were 
pre-processed as described in the corresponding source publications. GSE17737 and GSE18344 datasets con-
tained samples profiled on Affymetrix Mouse Genome 430 2.0 arrays. These arrays were normalised with frozen 
Robust Multi-array Analysis (fRMA), a procedure that allows microarrays to be pre-processed individually or in 
small batches and allows data to be combined into a single dataset for further analyses45. Since different profiling 
platforms contain different numbers of genes, we included 10, 634 genes in the analysis that were common to all 
platforms. A more detailed description is provided by Dvorkin-Gheva et al.44
To enable comparisons with smoking signatures from longer duration of smoking, we included samples from 
two additional GEO datasets (GSE52509 and GSE17737) that evaluated murine lung tissue expression changes 
following 24 weeks of smoking exposure. GSE52509 dataset was preprocessed as described in the correspond-
ing publication, while the samples from GSE17737 were normalized with fRMA44. Samples from both datasets 
were combined and the technical variation was removed by using Distance-Weighted Discrimination (DWD) 
method46.
Differential gene expression analysis. We used the “limma” package47 to compare gene expression profiles of 
smoke-exposed mice from each dataset with those of control mice pooled across all experiments. T-statistics were 
followed by Benjamini–Hochberg adjustment for multiple testing48.
Lung tissue transcriptome signature of COPD severity. We used data from Faner et al. to determine which genes 
were differentially expressed across COPD disease severity4. Briefly, lung tissue samples were obtained from 70 
former smokers with COPD who required thoracic surgery because of cancer or lung transplant. RNA samples 
were loaded onto an Affymetrix GeneChip Human Genome U219 Array Plate (Santa Clara, CA). The microarray 
data have been deposited in GEO (GSE69818)4. We identified 4,071 genes whose expression in lung tissue was 
different in patients with moderate or severe COPD (i.e. Global Initiative for Chronic Obstructive Lung Disease 
(GOLD) grades 3, 4) and those with mild COPD (defined by GOLD grades 1, 2). These differentially expressed 
genes will henceforth be referred to as “severe COPD signature”.
Overlap of murine and human genes. In order to compare results across murine and human studies, we restricted 
the analyses to murine genes that had a human ortholog using the BioMart-Ensembl database (release 88, March 
2017 http://www.ensembl.org/info/about/publications.html). We retained only those human genes on chromo-
some 1 to 22, or on chromosome X or Y, based on the position information from the BioMart-Ensembl database.
Enrichment of gene signatures. A hypergeometric (Fisher’s exact) test was used to test for significant over or 
under-representation of common genes from two different studies.
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